Mustang Bio, Inc. (MBIO)
MBIONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.4214
-0.0050 (-1.17%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $3.22m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.3503 to $1.43
- Average volume
- –
- Previous close
- $0.4264
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$624.0k | -$670.0k | -$1.06m | -$1.17m |
| Net income | -$468.0k | -$538.0k | -$955.0k | -$1.07m |
News
8 latest- MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer TherapyZacks · Jul 8, 2025
- Mustang Bio Announces FDA Orphan Drug Designation for MB-101 in Treatment of Recurrent Glioblastoma and High-Grade AstrocytomasQuiver Quantitative · Jul 7, 2025
- Mustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy Advancements RTTNews · Mar 5, 2025
- Mustang Bio, Inc. Regains Compliance with Nasdaq Capital Market Listing RequirementsQuiver Quantitative · Mar 5, 2025
- Mustang Bio Exits Facility And Sells Fixed Assets To AbbVie, Focusing On Advancing Clinical Trials RTTNews · Feb 28, 2025
- Mustang Bio, Inc. Announces Lease Exit and Asset Divestment to AbbVie for $1 MillionQuiver Quantitative · Feb 27, 2025
- Mustang Bio, Inc. Regains Compliance with Nasdaq Listing Requirements Following Recent Public OfferingQuiver Quantitative · Feb 11, 2025
- Mustang Bio, Inc. Regains Compliance with Nasdaq Listing Requirements Following Recent Public OfferingQuiver Quantitative · Feb 11, 2025
The company
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR-T therapies. Mustang's common stock is registered under the Securities Exchange Act of 1934, as amended, and Mustang files periodic reports with the U.S. Securities and Exchange Commission ("SEC"). Mustang was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.mustangbio.com.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- mustangbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.